KNOWLEDGE HUB

Tackling Obesity​

Insights on a pervasive global health challenge

Obesity is a pervasive global health challenge transcending border and, impacting millions with profound consequences to their well-being and quality of life.

Obesity prevalence could increase dramatically by 2035, to an approximately 25% of the global population classed as obese. This would mean a dramatically escalating burden on healthcare systems worldwide, fostering the rise of cardiovascular risk factors, and chronic conditions including diabetes, kidney and liver diseases. This is why there is so much interest in new obesity pharmacotherapies, with a rich pipeline of new agents, injectable and oral with a wide range of mechanisms of action from both large and emerging pharmaceutical companies.

IQVIA works with policy makers, healthcare systems, payers, pharmaceutical companies and researchers to tackle the obesity epidemic, identifying key trends, researching strategies and developing thought leadership to move forward, as well as providing solutions ranging from clinical research, real world data, market access and healthcare system capacity development, commercialisation and monitoring

Outlook for obesity in 2025: more than a transition year

A glimpse into the future AOM market: reimbursement, competition, benefits

Obesity in 2025 and beyond

Why 2025 lays the foundations for the long term evolution of the obesity space

Obesity Medications: changing the game for global health and the prescription medicines market?

WATCH ON DEMAND

A renaissance for cardiometabolic innovation

ACCESS THE WHITEPAPER

The Impact of GLP-1 Agonists on the MedTech Sector: Articulating a continued value proposition for devices

READ FULL ARTICLE

Blueprint for success

Stay ahead of the curve
IQVIA’s experts, thought leadership and solutions can provide the expertise and insights needed to understand the obesity landscape.
Fill in the form to talk to us today
Contact Us